Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant

Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant

Copyright © 2013 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 149(2013), 1 vom: 01. Okt., Seite 11-24
1. Verfasser: Yu, Yun-Zhou (VerfasserIn)
Weitere Verfasser: Wang, Shuang, Bai, Jie-Ying, Zhao, Meng, Chen, Ao, Wang, Wen-Bin, Chang, Qing, Liu, Si, Qiu, Wei-Yi, Pang, Xiao-Bin, Xu, Qing, Sun, Zhi-Wei
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2013
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Alzheimer's disease Carrier protein DNA vaccine Immunotherapy Toxin fragment Alzheimer Vaccines Amyloid beta-Peptides Epitopes mehr... Immunoglobulin G Malaria Vaccines PADRE 45 Peptide Fragments Vaccines, DNA amyloid beta-protein (1-15) amyloid beta-protein (1-42) Interleukin-4 207137-56-2 Interferon-gamma 82115-62-6
Beschreibung
Zusammenfassung:Copyright © 2013 Elsevier Inc. All rights reserved.
Active amyloid-beta (Aβ) immunotherapy is under investigation to prevent or treat Alzheimer disease (AD). We describe here the immunological characterization and protective effect of DNA epitope chimeric vaccines using 6 copies of Aβ1-15 fused with PADRE or toxin-derived carriers. These naked 6Aβ15-T-Hc chimeric DNA vaccines were demonstrated to induce robust anti-Aβ antibodies that could recognize Aβ oligomers and inhibit Aβ oligomer-mediated neurotoxicity, result in the reduction of cerebral Aβ load and Aβ oligomers, and improve cognitive function in AD mice, but did not stimulate Aβ-specific T cell responses. Notably, toxin-derived carriers as molecular adjuvants were able to substantially promote immune responses, overcome Aβ-associated hypo-responsiveness, and elicit long-term Aβ-specific antibody response in 6Aβ15-T-Hc-immunized AD mice. These findings suggest that our 6Aβ15-T-Hc DNA chimeric vaccines can be used as a safe and effective strategy for AD immunotherapy, and toxin-derived carrier proteins are effective molecular adjuvants of DNA epitope vaccines for Alzheimer's disease
Beschreibung:Date Completed 12.11.2013
Date Revised 17.09.2013
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2013.05.016